Jazz Pharmaceuticals (JAZZ) Non-Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 1.76% year-over-year to $7.3 billion in Q1 2026; TTM through Mar 2026 was $30.0 billion, a 1.22% decrease from a year earlier, with the FY2025 full-year figure at $7.5 billion, up 1.49% from the prior year.
• Non-Current Assets retreated to $7.3 billion in Q1 2026 per JAZZ's latest filing, from $7.5 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $9.3 billion in Q1 2022 and bottomed at $7.3 billion in Q1 2026.
• The 5-year median for Non-Current Assets is $7.8 billion (2022), against an average of $7.9 billion.
• Biggest YoY gain for Non-Current Assets was 158.19% in 2022; the steepest drop was 20.68% in 2022.
• Year by year, Non-Current Assets stood at $8.2 billion in 2022, then fell by 3.3% to $8.0 billion in 2023, then retreated by 7.22% to $7.4 billion in 2024, then increased by 1.49% to $7.5 billion in 2025, then declined by 2.89% to $7.3 billion in 2026.
• Per Business Quant, the three latest JAZZ Non-Current Assets figures stand at $7.3 billion (Q1 2026), $7.5 billion (Q4 2025), and $7.6 billion (Q3 2025).